Traws Pharma, Inc.

Traws Pharma's Tivoxavir Marboxil Shows Promise as Single-Dose H5N1 Bird Flu Treatment

5 months ago

• Traws Pharma's Tivoxavir Marboxil demonstrates encouraging results as a single-dose treatment for H5N1 avian influenza, marking a potential breakthrough. • Phase 1 trial data reveals that a single dose of Tivoxavir Marboxil maintains plasma drug levels above the effective concentration for over 23 days. • Preclinical studies highlight Tivoxavir Marboxil's potent activity against drug-resistant and highly pathogenic bird flu viruses, both in vitro and in vivo. • Phase 2 efficacy studies are planned to begin in H1 2025, bringing Tivoxavir Marboxil closer to becoming a viable treatment option for H5N1 bird flu.

Traws Pharma's Antiviral Programs Show Promise in Phase 1 Trials for COVID and Influenza

6 months ago

• Traws Pharma's ratutrelvir demonstrates potential as a once-daily monotherapy for COVID-19, eliminating the need for ritonavir and reducing clinical rebound risk. • Phase 1 data supports tivoxavir marboxil as a potential single-dose treatment for influenza, including pandemic strains like avian flu, showcasing good tolerability. • Both ratutrelvir and tivoxavir marboxil are advancing towards Phase 2 clinical trials, expected to commence in 2025, to further evaluate their efficacy. • Traws Pharma is also progressing its cancer program through investigator-sponsored trials, focusing on narazaciclib and rigosertib for multi-kinase inhibition.